Related Experiment Video
Updated: Apr 20, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
RAC1 and melanoma
1Yale University School of Medicine, Department of Dermatology, New Haven, Connecticut.
Abstract:
RAC1 is a GTPase member of the RAS superfamily, and RAC1(P29S) was recently identified as the third most common recurrent mutation in melanomas, affecting 4-7% of the patients. This is an oncogenic mutation, because the mutant protein remains mostly in its active GTP-bound form, and its ectopic expression increases the rate of normal melanocytes proliferation and migration. There is limited information regarding the functional role of RAC1(P29S) as a "driver" in human melanogenesis and as a cause for drug resistance. This commentary describes the latest data and provides evidence that supports the notion that RAC1 is activated even in melanoma cells that do not carry the mutation rendering it a good target for therapy. On the other hand, its role in conferring resistance to BRAF or MEK inhibitors is still in question.
Insights
The RAC1(P29S) mutation drives melanoma by promoting cell growth and migration. Activated RAC1, even without this mutation, presents a promising therapeutic target for melanoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- RAC1 is a GTPase in the RAS superfamily.
- The RAC1(P29S) mutation is the third most common recurrent mutation in melanomas, found in 4-7% of patients.
- This mutation results in a constitutively active GTP-bound RAC1 protein, enhancing melanocyte proliferation and migration.
Purpose of the Study:
- To review the functional role of RAC1(P29S) in melanoma.
- To explore RAC1 as a therapeutic target in melanoma, irrespective of mutation status.
- To investigate RAC1's role in drug resistance to BRAF and MEK inhibitors.
Main Methods:
- Literature review and data synthesis.
- Analysis of existing data on RAC1 activation in melanoma.
- Discussion of therapeutic implications.
Main Results:
- Ectopic expression of RAC1(P29S) increases melanocyte proliferation and migration.
- Evidence suggests RAC1 is activated in melanoma cells lacking the RAC1(P29S) mutation.
- The role of RAC1 in conferring resistance to BRAF or MEK inhibitors remains unclear.
Conclusions:
- Activated RAC1 is a potential therapeutic target in melanoma.
- Further research is needed to clarify RAC1's role in drug resistance mechanisms.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
MAPK Signaling Cascades
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
Abnormal Proliferation

